Drug intelligence / Profile preview

nituozumab

Development stage: Unknown
Lead developer: Mabpharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Nituozumab is a monoclonal antibody developed as an anti-cancer agent. It specifically targets the epidermal growth factor receptor (EGFR), a cell surface protein that is overexpressed in various cancers, including head and neck squamous cell carcinoma and glioblastoma. By binding to EGFR, nituozumab inhibits its activation and downstream signaling pathways involved in tumor cell proliferation, survival, angiogenesis, and metastasis. Nituozumab has been investigated primarily for the treatment of solid tumors expressing EGFR.

Brand names: nituozumab
Other names: nituozumab

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on nituozumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nituozumab.

Explore the full profile